TY  - JOUR

T1  - Cost-effectiveness (CE) of lapatinib plus capecitabine (L+C) in women with HER2+ metastatic breast cancer (MBC) who received prior therapy with trastuzumab (TZ) based on updated survival data from EGF100151.

JO  - J Clin Oncol

PY  - 2008/05/20

AU  - DeLea T

AU  - Tappenden P

AU  - Sofrygin O

AU  - Karnon J

AU  - Amonkar M

AU  - Browning D

AU  - Rudge HJ

AU  - Walker MD

ED  - 

VL  - 26

IS  - 15_suppl

SP  - 6559

Y2  - 2025/01/13

ER  -